Section Arrow
Quote
GLUE.NASDAQ
- Monte Rosa Therapeutics
Quotes are at least 15-min delayed:2026/10/18 21:42 EDT
Regular Hours
Last
 9.74
-0.38 (-3.75%)
Day High 
10.23 
Prev. Close
10.12 
1-M High
13.02 
Volume 
885.43K 
Bid
9.7
Ask
9.76
Day Low
9.705 
Open
10.18 
1-M Low
9.68 
Market Cap 
863.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 10.18 
20-SMA 11.04 
50-SMA 13.13 
52-W High 25.77 
52-W Low 8.9431 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.75/-2.22
Enterprise Value
898.17M
Balance Sheet
Book Value Per Share
5.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
123.67M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.